Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.57 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327177 | 0.93 | DYRK1A (0.66) | DYRK1AGSK3BCDC7CDK2KDM4C | |
| SCHEMBL12327008 | 0.81 | DYRK1A (0.47) | DYRK1AGSK3BCDC7CDK2KCNH2 | |
| SCHEMBL18976877 | 0.80 | DYRK1A (0.46) | DYRK1AGSK3BCDC7CDK2KCNH2 | |
| SCHEMBL2468525 | 0.79 | DYRK1A (0.50) | DYRK1AGSK3BCDC7CDK2KCNH2 | |
| SCHEMBL2464016 | 0.78 | CDC7 (0.43) | DYRK1AGSK3BCDC7CDK2KCNH2 | |
| SCHEMBL12354530 | 0.78 | KDM4C (0.51) | DYRK1AGSK3BKDM4CMAPK11MAPK14 | |
| SCHEMBL1921470 | 0.78 | KDM4C (0.51) | DYRK1AGSK3BKDM4CMAPK11MAPK14 | |
| SCHEMBL1923126 | 0.78 | KDM4C (0.51) | DYRK1AGSK3BKDM4CMAPK11MAPK14 | |
| SCHEMBL2464307 | 0.76 | DYRK1A (0.43) | DYRK1AGSK3BCDC7CDK2KCNH2 | |
| SCHEMBL25646426 | 0.73 | DYRK1A (1.00) | DYRK1AGSK3BKDM4CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014199171-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014199171-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-12-18 | — | — | WO | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| EP-2547677-A2 | INHIBITORS OF SEMICARABAZIDE - SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | DYRK1A 4705/4885GSK3B 3570/4885CDC7 4260/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | DYRK1A 4682/4885GSK3B 3629/4885CDC7 4456/4885 |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | DYRK1A 4354/4885GSK3B 2563/4885CDC7 2121/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | DYRK1A 4772/4885GSK3B 2785/4885CDC7 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.